

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934  
(Amendment No.5 and Amendment No.7)\*

QUESTCOR PHARMACEUTICALS INC.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

232808105

(CUSIP Number)

Joseph J. Giunta, Esq.  
Skadden, Arps, Slate, Meagher & Flom LLP  
300 South Grand Avenue  
Los Angeles, CA 90071  
(213) 687-5000

(Name, Address and Telephone Number of Person Authorized to Receive Notices  
and Communications)

January 12, 2004

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of ss.240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box .

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 232808105

1 NAME OF REPORTING PERSONS  
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS

Claudio Cavazza

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)   
(b)

3 SEC USE ONLY

4 SOURCE OF FUNDS

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED  
PURSUANT TO ITEMS 2(d) OR 2(e)

6 CITIZENSHIP OR PLACE OF ORGANIZATION

Italy

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER 0
	8	SHARED VOTING POWER 14,631,375
	9	SOLE DISPOSITIVE POWER 1,756,781
	10	SHARED DISPOSITIVE POWER 10,668,712

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

14,631,375

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

31.53%

14 TYPE OF REPORTING PERSON

IN

SCHEDULE 13D

CUSIP No. 232808105

1 NAME OF REPORTING PERSONS  
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS

Paolo Cavazza

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)   
(b)

3 SEC USE ONLY

4 SOURCE OF FUNDS

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED  
PURSUANT TO ITEMS 2(d) OR 2(e)

6 CITIZENSHIP OR PLACE OF ORGANIZATION

Italy

7 SOLE VOTING POWER  
0

8 SHARED VOTING POWER  
14,631,375

9 SOLE DISPOSITIVE POWER  
1,756,782

10 SHARED DISPOSITIVE POWER  
11,117,812

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

14,631,375

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES  
CERTAIN SHARES

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

31.53%

14 TYPE OF REPORTING PERSON

IN

SCHEDULE 13D

CUSIP No. 232808105

1 NAME OF REPORTING PERSONS  
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS

Sigma-Tau Finanziaria SpA

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)   
(b)

3 SEC USE ONLY

4 SOURCE OF FUNDS

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED  
PURSUANT TO ITEMS 2(d) OR 2(e)

6 CITIZENSHIP OR PLACE OF ORGANIZATION

Italy

7	SOLE VOTING POWER
NUMBER OF SHARES	0
8	SHARED VOTING POWER
BENEFICIALLY OWNED BY EACH	14,631,375
9	SOLE DISPOSITIVE POWER
REPORTING PERSON WITH	0
10	SHARED DISPOSITIVE POWER
	10,668,712

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

14,631,375

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES  
CERTAIN SHARES

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

31.53%

14 TYPE OF REPORTING PERSON

CO

SCHEDULE 13D

CUSIP No. 232808105

1 NAME OF REPORTING PERSONS  
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS

Sigma-Tau International S.A.

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)   
(b)

3 SEC USE ONLY

4 SOURCE OF FUNDS

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED  
PURSUANT TO ITEMS 2(d) OR 2(e)

6 CITIZENSHIP OR PLACE OF ORGANIZATION

Luxembourg

7	SOLE VOTING POWER
NUMBER OF SHARES	0
8	SHARED VOTING POWER
BENEFICIALLY OWNED BY	14,631,375
9	SOLE DISPOSITIVE POWER
EACH REPORTING PERSON WITH	0
10	SHARED DISPOSITIVE POWER
	10,668,712

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

14,631,375

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES  
CERTAIN SHARES

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

31.53%

14 TYPE OF REPORTING PERSON

CO

SCHEDULE 13D

-----  
 CUSIP No. 232808105  
 -----

1 NAME OF REPORTING PERSONS  
 I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS

Defiante Farmaceutica L.D.A.

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)   
 (b)

3 SEC USE ONLY

4 SOURCE OF FUNDS

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED  
 PURSUANT TO ITEMS 2(d) OR 2(e)

6 CITIZENSHIP OR PLACE OF ORGANIZATION

Portugal

NUMBER OF SHARES	7	SOLE VOTING POWER
	0	
BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	8	SHARED VOTING POWER
		14,631,375
	9	SOLE DISPOSITIVE POWER
		0
	10	SHARED DISPOSITIVE POWER
		2,025,315

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

14,631,375

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES  
 CERTAIN SHARES

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

31.53%

14 TYPE OF REPORTING PERSON

CO  
 -----

SCHEDULE 13D

CUSIP No. 232808105

1 NAME OF REPORTING PERSONS  
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS

Aptafin S.p.A.

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)   
(b)

3 SEC USE ONLY

4 SOURCE OF FUNDS

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED  
PURSUANT TO ITEMS 2(d) OR 2(e)

6 CITIZENSHIP OR PLACE OF ORGANIZATION

Italy

NUMBER OF SHARES	7	SOLE VOTING POWER 0
BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	8	SHARED VOTING POWER 14,631,375
	9	SOLE DISPOSITIVE POWER 0
	10	SHARED DISPOSITIVE POWER 449,100

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

14,631,375

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES  
CERTAIN SHARES

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

31.53%

14 TYPE OF REPORTING PERSON

CO

Amendment No. 5 and  
Amendment No. 7 to  
Statement on Schedule 13D

This Amendment No. 5 (the "Amendment No. 5") amends the Statement on Schedule 13D filed with the Securities and Exchange Commission ("SEC") on March 25, 2002 (the "Sigma/Defiante Schedule 13D"), as amended, relating to shares of the common stock, no par value (the "Common Stock"), of Questcor Pharmaceuticals Inc., a California corporation ("Questcor"). This Amendment No. 7 (the "Amendment No. 7" and, together with the Amendment No. 5, this "Statement") amends the Statement on Schedule 13D, filed with the SEC on August 7, 2001 (the "Cavazza/Sigma Schedule 13D" and, together with the Sigma/Defiante Schedule 13D, the "Schedule 13Ds"), as amended, relating to the shares of Common Stock. Pursuant to Rule 13d-2 of Regulation 13D-G promulgated under the Securities Exchange Act of 1934, as amended (the "Act"), this Amendment No. 5 is being filed on behalf of Sigma-Tau Finanziaria SpA, an Italian corporation ("Sigma Tau") and Defiante Farmaceutica L.D.A., a Portuguese corporation ("Defiante") (formerly known as Defiante Farmaceutica Unipessoal L.D.A.), and this Amendment No. 7 is being filed on behalf of Sigma-Tau International S.A., a Luxembourg corporation ("Sigma Tau International") (formerly known as Sigma-Tau Finance Holding S.A.), Aptafin S.p.A., an Italian corporation ("Aptafin"), Mr. Claudio Cavazza ("Mr. C. Cavazza") and Mr. Paolo Cavazza ("Mr. P. Cavazza" and, together with Mr. C. Cavazza, Sigma Tau International, Aptafin, Defiante and Sigma Tau, the "Reporting Persons").

Item 2. Identity and Background.

Item 2 of the Schedule 13Ds are hereby amended to add the following:

The business address of Sigma Tau International is 18 Avenue De La Porte Neuve, L-2227, Luxembourg. Sigma Tau International is a holding company whose principal assets consist of the common stock of various entities mainly in the pharmaceutical industry.

The business address of Aptafin is Viale Shakespeare 47, Rome, Italy, 00144. Mr. P. Cavazza owns, directly and indirectly, 100% of the capital stock of Aptafin, which is a company whose principal assets consist of equity interests in various entities mainly in the pharmaceutical industry.

The name, address, principal occupation or employment and citizenship of each of the executive officers and directors of Sigma-Tau, Sigma Tau International and Defiante are set forth in Schedule A hereto. Neither the Reporting Persons nor any of the persons listed on Schedule A has been, during the last five years, (a) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (b) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

Item 3. Source and Amount of Funds or Other Consideration.

Item 3 of the Schedule 13Ds are hereby amended to add the following:

On January 12, 2004, Defiante used its working capital to exercise warrants for the purchase of 759,493 shares of Common Stock for an aggregate purchase price of \$489,113.49.

Item 4. Purpose of the Transaction.

The purpose of the transaction was to acquire an equity investment interest in the Issuer.

None of the Reporting Parties has any present plans or proposals which relate to or would result in any transaction, change or event specified in clauses (a) through (j) of Item 4 of Schedule 13D.

Item 5. Interest in Securities of Questcor.

Item 5 of the Schedule 13Ds are hereby amended as follows:

The Reporting Persons, because they may be considered a "group" for

purposes of Section 13(d)(3) of the Act (the "Group"), may be deemed solely for purposes of U.S. securities laws to beneficially own (i) the 1,756,781 shares of Common Stock directly owned by Mr. C. Cavazza, (ii) the 1,756,782 shares of Common Stock directly owned by Mr. P. Cavazza, (iii) the 8,643,397 shares of Common Stock directly owned by Sigma Tau International, (iv) the 2,025,315 shares of Common Stock deemed to be directly beneficially owned by Defiante, and (v) the 449,100 shares of Common Stock deemed to be directly beneficially owned by Aptafin. This represents beneficial ownership of an aggregate of 14,631,375 shares of Common Stock. References to beneficial ownership are made herein solely with respect to U.S. securities laws and are not intended to refer or apply in any respect to any other issue under any other U.S. law.

(a) Percentage interest calculations for the Reporting Persons are based upon Questcor having 44,379,058 shares of Common Stock outstanding as of November 6, 2003 (the "Outstanding Shares"), as reported by the Issuer in the Issuer's Form 10-Q for the quarterly period ended September 30, 2003 filed with the SEC on November 12, 2003, which does not include 10,624,731 shares of Common Stock issuable upon the conversion of Questcor's Series B Preferred Stock (the "Preferred Stock"). The percentage interest calculation for the Voting Shares (as defined below) includes the present voting power of 10,624,731 shares of Common Stock issuable upon the conversion of the Preferred Stock. Each share of Preferred Stock is entitled to a number of votes equal to 0.875 times the number of shares of Common Stock issuable upon conversion of such shares of Preferred Stock, resulting in the voting equivalence of 9,296,640 shares of Common Stock (the "Converted Shares"). Accordingly, the total number of voting shares, based on the sum of the Outstanding Shares and the Converted Shares, is 53,675,698 (the "Voting Shares").

Mr. C. Cavazza

-----

Pursuant to Rule 13d-3 of the Act, Mr. C. Cavazza may be deemed to be the beneficial owner of 14,631,375 shares of Common Stock, which constitutes approximately 31.53% of the Outstanding Shares and 26.27% of the Voting Shares.

Mr. P. Cavazza

-----

Pursuant to Rule 13d-3 of the Act, Mr. P. Cavazza may be deemed to be the beneficial owner of 14,631,375 shares of Common Stock, which constitutes approximately 31.53% of the Outstanding Shares and 26.27% of the Voting Shares.

Sigma Tau International

-----

Pursuant to Rule 13d-3 of the Act, Sigma Tau International may be deemed to be the beneficial owner of 14,631,375 shares of Common Stock, which constitutes approximately 31.53% of the Outstanding Shares and 26.27% of the Voting Shares.

Sigma Tau

-----

Pursuant to Rule 13d-3 of the Act, Sigma Tau may be deemed to be the beneficial owner of 14,631,375 shares of Common Stock, which constitutes approximately 31.53% of the Outstanding Shares and 26.27% of the Voting Shares.

Defiante  
-----

Pursuant to Rule 13d-3 of the Act, Defiante may be deemed to be the beneficial owner of 14,631,375 shares of Common Stock, which constitutes approximately 31.53% of the Outstanding Shares and 26.27% of the Voting Shares.

Aptafin  
-----

Pursuant to Rule 13d-3 of the Act, Aptafin may be deemed to be the beneficial owner of 14,631,375 shares of Common Stock, which constitutes approximately 31.53% of the Outstanding Shares and 26.27% of the Voting Shares.

Except as set forth above, none of the Reporting Persons nor any of the persons listed on Schedule A beneficially owns any other shares of Common Stock.

(b) Mr. C. Cavazza  
-----

The number of shares of Common Stock as to which Mr. C. Cavazza has the sole power to vote or direct the vote is zero. The number of shares of Common Stock as to which Mr. C. Cavazza shares the power to vote or direct the vote is 14,631,375. The number of shares of Common Stock as to which Mr. C. Cavazza has the sole power to dispose or direct the disposition is 1,756,781. The number of shares of Common Stock as to which Mr. C. Cavazza shares the power to dispose or direct the disposition is 10,668,712.

Mr. P. Cavazza  
-----

The number of shares of Common Stock as to which Mr. P. Cavazza has the sole power to vote or direct the vote is zero. The number of shares of Common Stock as to which Mr. P. Cavazza shares the power to vote or direct the vote is 14,631,375. The number of shares of Common Stock as to which Mr. P. Cavazza has the sole power to dispose or direct the disposition is 1,756,782. The number of shares of Common Stock as to which Mr. P. Cavazza shares the power to dispose or direct the disposition is 11,117,812.

Sigma Tau International  
-----

The number of shares of Common Stock as to which Sigma Tau International has the sole power to vote or direct the vote is zero. The number of shares of Common Stock as to which Sigma Tau International shares the power to vote or direct the vote is 14,631,375. The number of shares of Common Stock as to which Sigma Tau International has the sole power to dispose or direct the disposition is zero. The number of shares of Common Stock as to which Sigma Tau International shares the power to dispose or direct the disposition is 10,668,712.

Sigma Tau

-----

The number of shares of Common Stock as to which Sigma Tau has the sole power to vote or direct the vote is zero. The number of shares of Common Stock as to which Sigma Tau shares the power to vote or direct the vote is 14,631,375. The number of shares of Common Stock as to which Sigma Tau has the sole power to dispose or direct the disposition is zero. The number of shares of Common Stock as to which Sigma Tau shares the power to dispose or direct the disposition is 10,668,712.

Defiante

-----

The number of shares of Common Stock as to which Defiante has the sole power to vote or direct the vote is zero. The number of shares of Common Stock as to which Defiante shares the power to vote or direct the vote is 14,631,375. The number of shares of Common Stock as to which Defiante has the sole power to dispose or direct the disposition is zero. The number of shares of Common Stock as to which Defiante shares the power to dispose or direct the disposition is 2,025,315.

Aptafin

-----

The number of shares of Common Stock as to which Aptafin has the sole power to vote or direct the vote is zero. The number of shares of Common Stock as to which Aptafin shares the power to vote or direct the vote is 14,631,375. The number of shares of Common Stock as to which Aptafin has the sole power to dispose or direct the disposition is zero. The number of shares of Common Stock as to which Aptafin shares the power to dispose or direct the disposition is 449,100.

Item 7. Material to be Filed as Exhibits.

-----

EXHIBIT 1 - Joint Filing Agreement dated January 13, 2004 by and between the Reporting Persons.

EXHIBIT 2 - Power of Attorney dated April 8, 2003 by and between the Reporting Persons(1).

---

(1) Incorporated by reference to Exhibit 1 of Form 4, filed with the SEC on May 9, 2003, relating to the shares of Common Stock.

Signatures

-----

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement with respect to Claudio Cavazza is true, complete and correct.

Dated: January 13, 2004

Claudio Cavazza

By: /s/ MAURIZIO TERENCEI  
-----  
Maurizio Terenzi, Attorney-in-  
fact for Claudio Cavazza

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement with respect to Paolo Cavazza is true, complete and correct.

Dated: January 13, 2004

Paolo Cavazza

By: /s/ MAURIZIO TERENCEI  
-----  
Maurizio Terenzi, Attorney-in-  
fact for Paolo Cavazza

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement with respect to Sigma-Tau Finanziaria SpA is true, complete and correct.

Dated: January 13, 2004

Sigma-Tau Finanziaria SpA

By: /s/ MAURIZIO TERENCEI  
-----  
Maurizio Terenzi, Attorney-in-  
fact for Sigma-Tau Finanziari SpA

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement with respect to Sigma-Tau International S.A. is true, complete and correct.

Dated: January 13, 2004

Sigma-Tau International S.A.

By: /s/ MAURIZIO TRENZI  
-----  
Maurizio Terenzi, Attorney-in-fact  
for Sigma-Tau International S.A.

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement with respect to Defiante Farmaceutica L.D.A. is true, complete and correct.

Dated: January 13, 2004

Defiante Farmaceutica L.D.A.

By: /s/ MAURIZIO TRENZI  
-----  
Maurizio Terenzi, Attorney-in-fact  
for Defiante Farmaceutica L.D.A.

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement with respect to Aptafin S.p.A. is true, complete and correct.

Dated: January 13, 2004

Aptafin S.p.A.

By: /s/ MAURIZIO TRENZI  
-----  
Maurizio Terenzi, Attorney-in-fact  
for Aptafin S.p.A.

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of the filing person), evidence of the representative's authority to sign on behalf of such person shall be filed with the statement: provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

## Schedule A

## EXECUTIVE OFFICERS AND DIRECTORS

## Sigma-Tau Finanziaria SpA

NAME	ADDRESS	TITLE	CITIZENSHIP
Claudio Cavazza	via Sudafrica,20, Rome Italy-00144	President	Italian
Mario Artali	via Sudafrica,20, Rome Italy-00144	Vice President	Italian
Antonio Nicolai	via Sudafrica,20, Rome Italy-00144	Managing Director	Italian
Vittorio Ripa di Meana	via Sudafrica,20, Rome Italy-00144	Director	Italian
Mauro Bove	via Sudafrica,20, Rome Italy-00144	Director	Italian
Piero Belletti	via Sudafrica,20, Rome Italy-00144	Director	Italian
Emilio Plate	via Sudafrica,20, Rome Italy-00144	Vice President	Italian
Maurizio Terenzi	via Sudafrica,20, Rome Italy-00144	Director	Italian
Enrico Cavazza	via Sudafrica,20, Rome Italy-00144	Director	Italian

Schedule A

EXECUTIVE OFFICERS AND DIRECTORS

Sigma-Tau International S.A.

NAME	ADDRESS	TITLE	CITIZENSHIP
Mario Artali	via Sudafrica,20, Rome Italy-00144	President	Italian
Jean-Marc Leonard	18 Avenue De La Porte Neuve L-2227 Luxembourg	Director	Luxembourg
Luca Checchinato	18 Avenue De La Porte Neuve L-2227 Luxembourg	Director	Luxembourg
Antonio Nicolai	via Sudafrica,20, Rome Italy-00144	Director	Italian
Mauro Bove	via Sudafrica,20, Rome Italy-00144	Director	Italian
Gustave Stoffel	Avenue Pasteur,6 LP-2310 Luxembourg	Director	Luxembourg
Maryse Santini	18 Avenue De La Porte Neuve L-2227 Luxembourg	Director	Luxembourg

Schedule A

EXECUTIVE OFFICERS AND DIRECTORS

Defiante Farmaceutica L.D.A.

NAME	ADDRESS	TITLE	CITIZENSHIP
Antonio Nicolai	via Sudafrica,20, Rome Italy-00144	Director	Italian
Raffaele Sanguigni	Via Portina Km. 30.400 - Pomezia (Rome) Italy	Director	Italian
Antonio Guilherme Rodrigues Frutuoso de Melo	Rua dos Ferreiros, 260 - Funchal - Madeira - Portugal 9000-082	Director	Portuguese
Pedro Moreira da Cruz Quintas	Rua dos Ferreiros, 260 - Funchal - Madeira - Portugal 9000-082	Director	Portuguese
Carla Emanuel Arruda Jardim Fernandes	Rua dos Ferreiros, 260 - Funchal - Madeira - Portugal 9000-082	Director	Portuguese

Schedule A

EXECUTIVE OFFICERS AND DIRECTORS

Aptafin S.p.A.

NAME	ADDRESS	TITLE	CITIZENSHIP
Cristina Cavazza	Viale Shakespeare, 47 Rome Italy- 00144	President	Italian
Piero Belletti	via Sudafrica,20, Rome Italy-00144	Managing Director	Italian
Antonio Nicolai	via Sudafrica,20, Rome Italy-00144	Director	Italian
Emanuela Cavazza	Viale Shakespeare 47 Rome Italy- 00144	Director	Italian

JOINT FILING AGREEMENT

The undersigned hereby agree that the statement on the Schedule 13D with respect to the Common Stock of Questcor Pharmaceuticals, Inc. dated as of January 13, 2004 is, and any amendments thereto signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(f) under the Securities Exchange Act of 1934.

Dated: January 13, 2004                      CLAUDIO CAVAZZA

By:            /s/ MAURIZIO TERENCEI  
-----  
                 Maurizio Terenzi, Attorney-in-fact  
                 for Claudio Cavazza

Dated: January 13, 2004                      PAOLO CAVAZZA

By:            /s/ MAURIZIO TERENCEI  
-----  
                 Maurizio Terenzi, Attorney-in-fact  
                 for Paolo Cavazza

Dated: January 13, 2004                      SIGMA TAU FINANZIARIA SPA

By:            /s/ MAURIZIO TERENCEI  
-----  
                 Maurizio Terenzi, Attorney-in-fact  
                 for Sigma-Tau Finanziari SpA

Dated: January 13, 2004                      SIGMA TAU INTERNATIONAL S.A.

By:            /s/ MAURIZIO TERENCEI  
                 Maurizio Terenzi, Attorney-in-fact  
                 for Sigma-Tau International S.A.

Dated: January 13, 2004                      DEFIANTE FARMACEUTICA L.D.A.

By:            /s/ MAURIZIO TERENCEI  
-----  
                 Maurizio Terenzi, Attorney-in-fact  
                 for Defiante Farmaceutica L.D.A.

Dated: January 13, 2004                      APTAFIN S.P.A.

By:            /s/ MAURIZIO TERENCEI  
-----  
                 Maurizio Terenzi, Attorney-in-fact  
                 for Aptafin S.p.A.